Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease

Abstract

Background: Recent advances have been made in understanding the pathophysiology of Alzheimer's disease (AD) and the role played by biomarkers. Amyloid PET has been used for diagnosis and as the primary outcome to support accelerated approval in AD. However, amyloid PET is costly, time consuming, and equipment dependent.

The paper